Related posts
Earnings mixed, Powell holds ratesFeds hold rates, markets partially reboundBitcoin and gold flirt with highs, stocks fadeThis summary was created by AI, based on 45 opinions in the last 12 months.
Pfizer Inc has seen a mixed bag of reviews from experts. Some see it as a value trap with little growth and tough industry conditions, while others view it as a strong long-term investment with a solid dividend yield and potential for growth from new drugs and acquisitions. The stock has been impacted by the transition away from Covid-related sales, patent cliffs, and disappointing drug trials, but some experts believe it is close to bottoming and offers good value for investors. Overall, the company is seen as having potential for growth but also facing challenges, making it a somewhat divisive stock among experts.
Their next report must show progress in their Seagen division or shares will fall.
Disappointing. Pharma needs to have a pipeline. Weight-loss and diabetes drug companies are the stars. Good company, but not a great stock. At some point, there will be a rally, though it might be a dead cat bounce. Don't own for the long term. If you have puts on it, you're in a decent position.
Strong dividend yield. Will continue to own shares. Weakness after the Covid-19 expected, but large decrease a surprise. However, strong pipeline of new drugs, and well known brand name. Expecting stock price to appreciate in the future.
Look at the 30-year chart. Stock's around the same price today as then, despite the 10s of billions in acquisitions over the years. Partly speaks to industry conditions, partly to lack of blockbuster drugs. Dividend secure. Terrible investment for decades. Yield is 6%.
Pays a 6% dividend, which is good as rates fall. The PE is low, because they don't a lot of high-quality drug prospects now, but they bought Seagen which he really likes.
At a pivotal point on the technical charts. Based down early this month and just moved up to 200-day MA, which is falling. If it can break that, it's positive for the stock. Really great dividend of 5.76% is fairly safe. If you're patient, it's OK. Stronger growth companies in healthcare, such as weight loss and diabetes. 8% growth rate.
US dividend stocks don't usually pay nearly as much as Canadian ones. If he's looking for income, there are tax and other advantages to owning Canadian dividend stocks, especially in non-registered portfolios.
Underperformer in the sector. Not in a growth area, which is weight loss right now. So he'd probably look at LLY and NVO. Those pipelines are probably going to be fairly robust.
Ex-Covid, this is one of the biggest pharmas in the world that generates huge cash flow that supports a 6% dividend. He targets mid-$40s.
(Analysts’ price target is $32.10)Selloff due to less demand from post Covid-19 selling. Believes was overvalued during. However, right now - could be a good time to buy. Expecting share price to recover to $40-$45. Would hold - good for long term investors. Owns in portfolio.
Great company, that has turned the corner. Solid dividend with lots of cash on the balance sheet.
It hasn't done much since the 1990's except during Covid. It's surprising that it is hiring a chief strategy and innovation officer that has been down on the stock for a decade, except for the oncology component.
Believes stock is bottoming out right now. New products are going to present opportunity. ~5.5% also good.
They pay over a 6% dividend and trades at 9x PE. A wonderful story here. Will grow at a realistic 3-8% as you collect that dividend.
It is down 60% from its peak and trading at 10X forward earnings with a 6% dividend yield, It took the windfall cash from the Covid vaccines, etc. and re-invested in new growth areas such as cancer, diabetic and weight loss treatments/ drugs., It is out of favour and there is potential for growth.
Buy 11 Hold 15 Sell 0
It reports Wednesday. He wants to hear how their purchase of Seagan has impacted the numbers.
Pfizer Inc is a American stock, trading under the symbol PFE-N on the New York Stock Exchange (PFE). It is usually referred to as NYSE:PFE or PFE-N
In the last year, 36 stock analysts published opinions about PFE-N. 12 analysts recommended to BUY the stock. 19 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Pfizer Inc.
Pfizer Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Pfizer Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
36 stock analysts on Stockchase covered Pfizer Inc In the last year. It is a trending stock that is worth watching.
On 2024-07-26, Pfizer Inc (PFE-N) stock closed at a price of $30.77.